Related Experiment Video
Updated: Jun 11, 2025

Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line
Published on: May 10, 2017
The risk of cancer in pediatric-onset immune-mediated inflammatory diseases - A nationwide study
Andrea Ehrström1, Sabine Jansson1, Marianne Hørby Jørgensen2
1Department of Pediatric and Adolescent Medicine, Copenhagen University Hospital, Amager and Hvidovre Hospital, Hvidovre, Denmark; Copenhagen Center for Inflammatory Bowel Disease in Children, Adolescents, and Adults, Hvidovre Hospital, University of Copenhagen, Hvidovre, Denmark.
Insights
Pediatric-onset immune-mediated inflammatory diseases (pIMID) significantly increase long-term cancer risk. Certain treatments like thiopurines and anti-TNFα are linked to higher risks of lymphoma and skin cancer.
Area of Science:
- Pediatric Rheumatology
- Oncology
- Immunology
Background:
- Adult-onset immune-mediated inflammatory diseases (IMID) are known cancer risk factors.
- Data on cancer risk in pediatric-onset IMID (pIMID) is limited.
- Understanding pIMID's long-term cancer implications is crucial for early intervention.
Purpose of the Study:
- To estimate the long-term cancer risk in patients with pIMID.
- To investigate the association between specific medical treatments and cancer development in pIMID patients.
- To inform clinical management and surveillance strategies for pIMID.
Main Methods:
- Nationwide Danish health registers used to identify 12,664 pIMID patients (diagnosed 1980-2018).
- pIMID patients were matched with 109,274 reference individuals.
- Cancer risk assessed, with specific focus on immunomodulators and anti-TNFα therapies.
Main Results:
- pIMID patients exhibited a twofold higher cancer risk (AHR 2.2) compared to controls.
- Thiopurine treatment correlated with increased lymphoma and skin cancer risks (AHR 6.1 for both).
- Anti-TNFα treatment was associated with a higher risk of lymphoma (AHR 4.9).
Conclusions:
- pIMID is associated with elevated cancer risk extending into adulthood.
- Thiopurine and anti-TNFα therapies require careful consideration due to potential links with specific cancers.
- Individualized immunotherapy and vigilant cancer surveillance are essential for pIMID management.
Background And Objectives:
Adult-onset immune-mediated inflammatory disease (IMID) increases the risk of several cancers. However, data on pediatric-onset IMID (pIMID) remains scarce. We estimated the long-term cancer risk in pIMID and the association between medical treatment and specific cancers.
Methods:
We used the nationwide Danish health registers to identify pIMID patients diagnosed from Jan 1, 1980 to Dec 31, 2018. Patients were matched with ten reference individuals based on age, sex, and residence. The primary exposure was pIMID, including autoimmune hepatitis, primary sclerosing cholangitis, Crohn's disease, ulcerative colitis, juvenile idiopathic arthritis, systemic lupus erythematosus, vasculitis, and connective tissue disease. Secondary exposures were immunomodulators and tumor necrosis factor-α antagonists (anti-TNFα). The primary outcome was cancer. Estimates are presented as hazard ratios adjusted for family income at diagnosis (AHR).
Results:
We included 12,664 pIMID patients and 109,274 reference individuals. Median follow-up time was 10.6 (interquartile range: 5.4-17.7) years for patients and 10.2 (interquartile range: 5.2-17.3) years for reference individuals. Patients with pIMID had a twofold higher cancer risk (AHR 2.2 [95 % confidence interval (CI): 1.8-2.6]) compared with reference individuals. Thiopurine treatment was associated with a higher risk of lymphoma (AHR 6.1 [95%CI: 2.2-16.8]) and skin cancer (AHR 6.1 [95%CI: 2.4-15.4]). Anti-TNFα treatment was associated with a higher risk of lymphoma (AHR 4.9 [95%CI: 1.1-22.6]).
Conclusions:
We found an increased cancer risk in patients with pIMID followed into adulthood. Additionally, thiopurines and anti-TNFα were associated with increased lymphoma and skin cancer risks. This highlights the importance of individualized immunotherapy and cancer surveillance.
More Related Videos
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
05:31Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels
Published on: August 7, 2017
Related Concept Videos
Cancer Prevention
Some...
Immunodeficiency Diseases
There are three main causes of immunodeficiency...
Tumor Immunotherapy
Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune...
Psychoneuroimmunology: Diabetes and Cancer